Specifically, the criteria for AML-MR have been modified in both WHO-HAEM5 and ICC to include MR gene mutations, regardless of history of antecedent hematologic malignancy or myelodysplasia-related cytogenetic abnormalities, which would potentially shift more cases previously classified as MPAL to AML-MR. This evidence concerns the gene NR3C2 and acute myeloid leukemia.